Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
Authors
Keywords
-
Journal
ONCOLOGY
Volume 81, Issue 3-4, Pages 251-258
Publisher
S. Karger AG
Online
2011-11-23
DOI
10.1159/000334454
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- (2010) Yu-Yun Shao et al. CANCER
- Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009)
- (2010) Shigeki Arii et al. HEPATOLOGY RESEARCH
- Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma
- (2010) Shouta Iwadou et al. LIVER INTERNATIONAL
- Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma
- (2010) Beom Kyung Kim et al. LIVER INTERNATIONAL
- Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan
- (2010) Masatoshi Kudo et al. ONCOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study
- (2009) Salvatore Del Prete et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-γ-carboxy prothrombin production in hepatocellular carcinoma
- (2009) Murata INTERNATIONAL JOURNAL OF ONCOLOGY
- Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival
- (2009) Ahsun Riaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum -Fetoprotein Response as a Surrogate for Clinical Outcome in Patients Receiving Systemic Therapy for Advanced Hepatocellular Carcinoma
- (2009) S. R. Vora et al. ONCOLOGIST
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
- (2008) Stephen L. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC
- (2008) Hidenori Toyoda et al. JOURNAL OF HEPATOLOGY
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now